Catalyst Pharmaceuticals (CPRX) CEO Rich Daly on the company's strong 1Q, growth drivers, and its cash-rich position in a challenging market. Daly discusses the company's pipeline, including plans to expand its product for Lambert-Eaton Myasthenic Syndrome (LEMS) into the oncology space and potential M&A opportunities in the rare disease space.